While the demand for discovery and development of novel therapies to address drug-resistant infections has been clearly elucidated again and again, the big biopharmaceutical industry players continue to pull out – but it remains to be seen whether new efforts to drive early-stage R&D can fill the gap.
Despite regulatory incentives like the GAIN (Generating Antibiotic Incentives Now) provisions the US FDA introduced in 2012, the antimicrobial resistance...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
